(Redirected from Avodart)
Jump to: navigation, search
Systematic (IUPAC) name
(5α, 17β)-N-{2,5 bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
CAS number 164656-23-9
ATC code G04CB02
PubChem 152945
DrugBank APRD00385
Chemical data
Formula C27H30F6N2O2 
Mol. mass 528.53 g/mol
Pharmacokinetic data
Bioavailability 60%
Protein binding 99%
Metabolism Hepatic (CYP3A4-mediated)
Half life 5 weeks
Excretion Fecal
Therapeutic considerations
Pregnancy cat.

X(US) Not to be handled by pregnant women

Legal status

POM(UK) -only(US)

Routes Oral

WikiDoc Resources for



Most recent articles on Dutasteride

Most cited articles on Dutasteride

Review articles on Dutasteride

Articles on Dutasteride in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dutasteride

Images of Dutasteride

Photos of Dutasteride

Podcasts & MP3s on Dutasteride

Videos on Dutasteride

Evidence Based Medicine

Cochrane Collaboration on Dutasteride

Bandolier on Dutasteride

TRIP on Dutasteride

Clinical Trials

Ongoing Trials on Dutasteride at Clinical Trials.gov

Trial results on Dutasteride

Clinical Trials on Dutasteride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dutasteride

NICE Guidance on Dutasteride


FDA on Dutasteride

CDC on Dutasteride


Books on Dutasteride


Dutasteride in the news

Be alerted to news on Dutasteride

News trends on Dutasteride


Blogs on Dutasteride


Definitions of Dutasteride

Patient Resources / Community

Patient resources on Dutasteride

Discussion groups on Dutasteride

Patient Handouts on Dutasteride

Directions to Hospitals Treating Dutasteride

Risk calculators and risk factors for Dutasteride

Healthcare Provider Resources

Symptoms of Dutasteride

Causes & Risk Factors for Dutasteride

Diagnostic studies for Dutasteride

Treatment of Dutasteride

Continuing Medical Education (CME)

CME Programs on Dutasteride


Dutasteride en Espanol

Dutasteride en Francais


Dutasteride in the Marketplace

Patents on Dutasteride

Experimental / Informatics

List of terms related to Dutasteride


Dutasteride (marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) is a 5-alpha-reductase inhibitor, a drug which inhibits the conversion of testosterone into dihydrotestosterone (DHT). It is used to treat conditions caused by DHT, such as benign prostatic hyperplasia (BPH).

Classification and Method of Action

Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group. Dutasteride inhibits both isoforms of 5-alpha reductase, while finasteride inhibits only one. But a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH.


While dutasteride is officially approved to treat enlargement of the prostate gland. Clinical trials for dutasteride as a hair loss drug were undertaken, but called off in late 2002. The reason the trials were called off is not publicly known. Industry sources speculate that Avodart would have been seen as too similar to Propecia to have proved profitable as a hair loss treatment.

In December 2006, Avodart manufacturer GlaxoSmithKline embarked on a new Phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5mg) for the treatment of male pattern baldness in the vertex region of the scalp (types IIIv, IV and V on the Hamilton-Norwood scale).[1] The future impact that this study will have on the FDA's approval or disapproval of Avodart for the treatment of male pattern baldness in the United States is yet to be determined.

See also

External links


  1. ClinicalTrials.gov NCT00441116